High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide

Authors:	Maryam?Pourabdollah,Mohammad?Bahmanyar,Eshetu?G.?Atenafu,Donna?Reece,Jian?Hou,Hong?Chang author-information" > author-information__contact u-icon-before" > mailto:hong.chang@uhn.ca" title=" hong.chang@uhn.ca" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author

Affiliation:	1.Department of Laboratory Medicine and Pathobiology,University of Toronto,Toronto,Canada;2.Department of Biostatistics,University of Toronto,Toronto,Canada;3.Department of Hematology and Medical Oncology,University of Toronto,Toronto,Canada;4.Department of Hematology,Shanghai Chang Zheng Hospital,Shanghai,China;5.Department of Laboratory Hematology,University Health Network,Toronto,Canada

Abstract:	The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P?=?0.0029 and P?P?=?0.0014 and P?

Keywords:
本文献已被 SpringerLink 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏